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Screening for prostate cancer is worthwhile only if it detects potentially life-threatening tumors among asymptomatic men at a stage when lesions are curable, and if the prospect of benefit outweighs the potential for harm. 1,2 The debate over the value of prostate cancer screening is often fuelled by vigorous advocacy rather than the presence of robust evidence. 1 Annually, over 500,000 men worldwide are diagnosed with prostate cancer. Screening by serum prostate-specific antigen (PSA) testing is appealing because it identifies cancers localized to the prostate gland that are hence potentially curable. In contrast, most men diagnosed clinically already have locally advanced or (in a minority) metastatic cancers with a poorer prognosis depending on the extent of spread. Increasing age is a clearly established risk factor for prostate cancer. Having an affected first-degree relative doubles the risk of developing prostate cancer, although major susceptibility genes account for only 5-10% of cases. 1 Secondary prevention through screening is thus the only population-based approach available. 1 Here we review the evidence for prostate cancer screening with reference to UK criteria for the evaluation of a screening program. 3 Some histological evidence of prostate cancer is almost ubiquitous in old age, but the risk of a man aged 50 years dying from prostate cancer is about 3%. 1 Estimates of the proportion of screen-detected prostate cancers that would not become clinically apparent in a man's lifetime vary from 48% to 84%, 4,5 because prostate cancer is highly aggressive in a minority but indolent in the majority. Rate of disease progression within different histological grades is highly variable, especially amongst men with Gleason score 6, 1 and there are currently no established markers of biologically aggressive prostate cancer to predict prognosis in the majority of men with localized screen-detected prostate cancer.
PSA is the main screening test used to indicate when biopsy is required. PSA levels measured from stored serum taken in the pre-PSA era to avoid surveillance bias were strongly associated with future incidence of clinically defined prostate cancer and consequent mortality. 6, 7 Findings from the Prostate Cancer Prevention Trial (PCPT) indicate there is a continuum of increased risk of prostate cancer with increasing PSA levels, even at levels well below currently recommended cutoffs, 8 and no threshold PSA value for undertaking a diagnostic biopsy offers simultaneously high SENSITIVITY and SPECIFICITY. 9 In the PCPT, all men underwent prostate biopsy after 7 years of follow-up, regardless of PSA or digital rectal examination findings, to avoid VERIFICATION BIAS. 8 Previously un detected prostate cancer was diagnosed by biopsy in 15% of 2,950 men aged 62-91 years with PSA levels <3.0 ng/ml at baseline and <4.0 ng/ml at all annual follow-up visits. 8 PSA sensitivity at threshold levels of 1.1, 2.6 and 4.1 ng/ml was 83.4, 40.5 and 20.5%, and specificity was 38.9, 81.1 and 93.8%. 9 Some of the tumors detected at these low levels of PSA might be clinically important. In the PCPT 15% of cancers detected after biopsy in men with PSA values less than 4.0 ng/ml were high grade (Gleason score 7 or more) 8 and in the Physicians' Health Study 6 risk of subsequent clinically defined prostate cancer increased in parallel with increasing levels of PSA in the normal range. In recent screening trials, concerns about an appropriate cutoff point led to all men with PSA levels of 3 ng/ml and higher undergoing biopsy, 1 and a threshold of 2.6 ng/ ml has been recommended. Such reactions fail to appreciate that screening is a program not a test, and that it is essential to evaluate what happens at all stages of the screening process. 1 The large difference between a man's risk of death from prostate cancer (about 3%) and lifetime risk of having microscopic evidence of prostate cancer (42% for a man of 50 years), 1 suggests that the vast majority of prostate cancers detected by screening will be clinically unimportant. Currently, the key dilemma is that screening tests cannot differentiate screen-detected cancers that have low biological like lihood of progression from those with aggressive potential. 1 Published studies about the effectiveness of the main treatments for localized prostate cancer (radical prostatectomy, radical radiotherapy, brachytherapy, and active monitoring) tend to be observational in design and small in scale, and data are insufficiently robust. A randomized controlled trial from Scandinavia showed that radical prostatectomy for localized prostate cancer reduced the risk of allcause and prostate-cancer-specific mortality at 10 years by approximately 25% and 44%, respectively, compared with watchful waiting. 10 Only 11% of the men had screen-detected prostate cancer, however. This trial provides little direct information about the potential effectiveness of radical prostatectomy in prostate cancer screening programs. Patients are increasingly choosing active monitoring, involving regular PSA tests and clinical and sometimes histological follow-up, but the most appropriate frequency and form of follow-up remains undefined (RM Martin, unpublished data). Treatments for localized prostate cancer can have deleterious side effects, 2 and evidence from randomized trials about the effectiveness and side effects of treatment for screen-detected disease is urgently required.
It has been suggested that the decline in prostate cancer mortality during the 1990s reported in Canada, the US, Austria, France, Germany, Italy and the UK was due to the increased use of PSA screening. The pattern of change in mortality, however, is inconsistent between and within countries. 11 In the US, the mortality decline seems to have occurred very soon after the start of PSA testing, before any effects would be expected. In the UK and other countries, mortality declined with no major increase in PSA testing. 11 Other factors, including improved treatment of clinically detected disease, probably contributed. A study comparing cohorts of men from US areas where there was rapid uptake of PSA screening and prostate cancer treatment with those where testing was much less common, found no differences in mortality. 12 Robust evidence can only come from randomized trials of screening programs; these are underway in Europe (ERSPC), the US (PLCO) and the UK (Comparison arm for ProtecT trial, CAP).
PSA screening might result in considerable overdiagnosis and overtreatment of clinically insignificant prostate cancer, 4 with little evidence of mortality benefit, 12 and the prospect of substantial treatment-related morbidity. 2 For every million men tested using PSA, about 100,000 would have raised PSA and face anxiety over possible cancer and the need for biopsy. 1 Approximately 20,000 men would be diagnosed with cancer, and 80,000 face an unquantified future risk of prostate cancer. If half of those diagnosed with localized disease (10,000) were to undergo radical prostatectomy, conservative estimates suggest that 10 would die of the operation, 300 would develop severe urinary incontinence and 4,000 impotence. The number whose prostate cancer would eventually have impinged upon their lives is currently unknown, as is the number of deaths that would have been prevented. Until biological markers are identified that will predict aggressive cancers and aid the individualization of patient management, screening for prostate cancer is unjustified outside randomized controlled trials investigating its effects.
